The study team found that DTP3 could be used to treat people with myeloma that had come back or when treatment had stopped working.
This study was open to people to join between 2016 and 2017.
These results were published in 2018.
About this study
The team looked at 3 different doses of DTP3.
3 people took part in this study. Each person had a different dose of DTP3.
2 people had 1 cycle of treatment
of DTP3 and 1 person had 3 cycles, each lasting 1 month. No one reported any side effects that might stop their treatment.
Doctors look at substances in the urine and blood (biomarkers
) called free light chains and paraprotein. This helps to find out how well treatments might work for myeloma.
When the researchers looked at these they found that for 1 person these had decreased in the blood. This was in keeping with their myeloma which was not getting any worse.
This person’s free light chains and paraprotein stayed this way for 3 treatment cycles of DTP3 before their myeloma started to get worse again.
The team looked at blood test results and bone marrow
test results to find what was happening in the body. They found that DTP3 triggered programmed cell death (apoptosis
) for myeloma cells but not for healthy cells. This meant it killed myeloma cells but didn’t affect healthy cells.
The study team concluded that these initial results are encouraging. And they are planning to do larger clinical trials to find how well DTP3 might work for people with myeloma.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.